Comment from Grifols

Summary: Biomat USA, Inc., representing Grifols Source Plasma establishments, supports the FDA's efforts to clarify expectations for responding to Form 483 observations. The commenter requests specific clarifications regarding the necessity of tables of contents for short responses, the handling of verbal discussion items, and the specific triggers for interim reporting.